Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HIV CTL MEP 1000 micrograms, 19 months per subject · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HIV CTL MEP 1000 micrograms, 19 months per subject | BIOLOGICAL | - |
Inclusion Criteria: * 18 years of age diagnosed with HIV and on stable HAART for a minimum of six months * CD4 T-cell count greater than and equal to 350/mm3 at screening * No reported CD4 T-cell count less than 350/mm3 at any time before screening * Viral load less than 50 copies/mL at screening a...
Top 20 of 28 competitors
HIV CTL MEP 1000 micrograms is an investigational monoclonal antibody being studied for the treatment of HIV Infections. It is currently in Phase 1 clinical development. The drug is being evaluated in a completed clinical trial that enrolled 60 adult participants in the United States.
HIV CTL MEP 1000 micrograms is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical research on this monoclonal antibody for the treatment of HIV Infections.
HIV CTL MEP 1000 micrograms is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial for this monoclonal antibody has been completed, and it remains in early-stage clinical research for HIV Infections.
HIV CTL MEP 1000 micrograms has one completed clinical trial registered under NCT00195234, titled "Study Evaluating Vaccine in Adults With HIV." This Phase 1 trial enrolled 60 participants with HIV Infections in the United States. The study was randomized and double-blind, though it did not use a control group.
HIV CTL MEP 1000 micrograms is a monoclonal antibody, not a vaccine. Although its clinical trial is titled "Study Evaluating Vaccine in Adults With HIV," the drug itself is classified as a monoclonal antibody. It is being investigated for its potential role in treating HIV Infections.